Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer

Shashank Sama; Sterling Rosqvist; Talicia Savage; Lesley Lomo; Kiera Sibbald; Alli Straubhar; Theresa L Werner

doi:10.1016/j.gore.2024.101412

Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer

Gynecol Oncol Rep. 2024 May 11:53:101412. doi: 10.1016/j.gore.2024.101412. eCollection 2024 Jun.

Authors

Shashank Sama¹, Sterling Rosqvist², Talicia Savage¹, Lesley Lomo¹, Kiera Sibbald², Alli Straubhar³, Theresa L Werner¹

Affiliations

¹ Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
² University of Utah, Salt Lake City, UT, USA.
³ Intermountain Hospital, USA.

Abstract

Low grade serous ovarian cancers (LGSOC) in an advanced setting have limited systemic treatment options. In this paper we report a case of metastatic LGSOC harboring a BRAF mutation, treated with dabrafenib. We discuss the clinical, pathologic and molecular characteristics as well as surgical considerations and ongoing investigations in LGSOC.

Keywords: BRAF inhibitor; Low grade serous ovarian cancer.

Publication types

Review